Some tumors contain factors that may block metastasis

In a recent issue of Cancer Research, a journal of the American Association for Cancer Research, Raúl A. Ruggiero, Ph.D., a biological researcher at the division of experimental medicine at the National Academy of Medicine in Buenos Aires, Argentina, described this novel mechanism.

Ruggiero and colleagues used bioanalytical methods of ion electrospray mass and tandem mass spectrometry to identify the factors that lead to metastasis resistance in laboratory models of localized cancer, a phenomenon called “concomitant tumor resistance” in which factors in a tumor can inhibit its own metastasis.

“The main cause of death in cancer patients is associated much more with metastasis rather than with the growth of a localized tumor, which generally can be surgically removed,” he said.

Ruggiero's laboratory found that the presence of variant forms of the amino acid tyrosine were responsible for concomitant tumor resistance. In tumor models where these variants of tyrosine were present, the localized tumor did not tend to metastasize as fast as tumors lacking the variants.

Currently, tumor metastasis is treated with various chemotherapy regimens, but Ruggiero said the results of this sort of treatment are usually disappointing. He hopes that these tyrosine variants could be developed as a simple and safe type of therapy to retard metastatic growth.

“Both meta- and ortho-tyrosine have many attractive features. They exert antitumor effects at very low concentrations, are naturally produced in the proper tumor bearing organism, and do not appear to exert any toxic side effects,” said Ruggiero. “If these findings are confirmed we could develop new and more harmless means to manage malignant disease.”

Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards to young investigators, and it also funds cutting-edge research projects conducted by senior researchers. The AACR has numerous fruitful collaborations with organizations and foundations in the U.S. and abroad, and functions as the Scientific Partner of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame.

The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care, and Educational Workshops are held for the training of young cancer investigators. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. In 2010, AACR journals received 20 percent of the total number of citations given to oncology journals. The AACR also publishes Cancer Today, a magazine for cancer patients, survivors and their caregivers, which provides practical knowledge and new hope for cancer survivors. A major goal of the AACR is to educate the general public and policymakers about the value of cancer research in improving public health, the vital importance of increases in sustained funding for cancer research and biomedical science, and the need for national policies that foster innovation and the acceleration of progress against the 200 diseases we call cancer.